Enhanced apoptosis in the thymus of transgenic mice expressing constitutively activated forms of human Rac2GTPase - PubMed (original) (raw)
. 1997 Jul 31;15(5):601-5.
doi: 10.1038/sj.onc.1201378.
Affiliations
- PMID: 9247314
- DOI: 10.1038/sj.onc.1201378
Enhanced apoptosis in the thymus of transgenic mice expressing constitutively activated forms of human Rac2GTPase
P Lorès et al. Oncogene. 1997.
Abstract
Rac proteins constitute a subgroup of the Rho family of small GTPases and include Rac1, which is expressed ubiquitously, and Rac2, a highly homologous protein only expressed in myelo-monocytic and lymphoid cell lineages. In fibroblasts, Rac1 plays a crucial role in control of actin cytoskeleton organisation, cell growth and Ras-induced transformation. In phagocytes, Rac1 and Rac2 regulate a specific enzymatic complex, NADPH oxidase. These multiple functions have been ascribed to Rac proteins only on the basis of cell culture and in vitro biochemical studies. To examine the role of Rac2 in vivo in a T cell lineage, we have expressed either wild-type or constitutively-activated forms of human Rac2 (Rac2V12 and Rac2L61) in transgenic mice under control of the thymus specific lck proximal promoter. We report here a striking atrophy of the thymus in mice expressing even low levels of either of the activated mutants of Rac2, while expression of Rac2wt has no effect. This phenotype is correlated with a marked decrease in the number of double positive (CD4+ CD8+) and single positive (CD4+ CD8- and CD8+ CD4-) thymocytes. Cellular and molecular analyses demonstrate that this defect is due to an increase in apoptosis among thymocytes. As Rac2 is normally expressed in thymocytes and activated T cells, we propose that Rac2 dependent pathways could play an important role in control of growth and death of T cells.
Similar articles
- Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth.
Murphy GA, Solski PA, Jillian SA, Pérez de la Ossa P, D'Eustachio P, Der CJ, Rush MG. Murphy GA, et al. Oncogene. 1999 Jul 1;18(26):3831-45. doi: 10.1038/sj.onc.1202758. Oncogene. 1999. PMID: 10445846 - Expression of activated CDC42 induces T cell apoptosis in thymus and peripheral lymph organs via different pathways.
Na S, Li B, Grewal IS, Enslen H, Davis RJ, Hanke JH, Flavell RA. Na S, et al. Oncogene. 1999 Dec 23;18(56):7966-74. doi: 10.1038/sj.onc.1203122. Oncogene. 1999. PMID: 10637507 - Susceptibility and resistance to antigen-induced apoptosis in the thymus of transgenic mice.
Tarazona R, Williams O, Moskophidis D, Smyth LA, Tanaka Y, Murdjeva M, Wack A, Mamalaki C, Kioussis D. Tarazona R, et al. J Immunol. 1998 Jun 1;160(11):5397-403. J Immunol. 1998. PMID: 9605140 - Rac GTPases in human diseases.
Pai SY, Kim C, Williams DA. Pai SY, et al. Dis Markers. 2010;29(3-4):177-87. doi: 10.3233/DMA-2010-0738. Dis Markers. 2010. PMID: 21178276 Free PMC article. Review. - RAC2 GTPase deficiency and myeloid cell dysfunction in human and mouse.
Gu Y, Williams DA. Gu Y, et al. J Pediatr Hematol Oncol. 2002 Dec;24(9):791-4. doi: 10.1097/00043426-200212000-00027. J Pediatr Hematol Oncol. 2002. PMID: 12468931 Review.
Cited by
- Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing.
Mishra AK, Rodriguez M, Torres AY, Smith M, Rodriguez A, Bond A, Morrissey MA, Montell DJ. Mishra AK, et al. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2310221120. doi: 10.1073/pnas.2310221120. Epub 2023 Dec 18. Proc Natl Acad Sci U S A. 2023. PMID: 38109551 Free PMC article. - Combined Immunodeficiency Caused by a Novel De Novo Gain-of-Function RAC2 Mutation.
Zhang L, Chen Z, Li W, Liu Q, Wang Y, Chen X, Tian Z, Yang Q, An Y, Zhang Z, Mao H, Tang X, Lv G, Zhao X. Zhang L, et al. J Clin Immunol. 2022 Aug;42(6):1280-1292. doi: 10.1007/s10875-022-01288-4. Epub 2022 May 21. J Clin Immunol. 2022. PMID: 35596857 - A gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency.
Lagresle-Peyrou C, Olichon A, Sadek H, Roche P, Tardy C, Da Silva C, Garrigue A, Fischer A, Moshous D, Collette Y, Picard C, Casanova JL, André I, Cavazzana M. Lagresle-Peyrou C, et al. Haematologica. 2021 Feb 1;106(2):404-411. doi: 10.3324/haematol.2019.230250. Haematologica. 2021. PMID: 31919089 Free PMC article. - Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects.
Hsu AP, Donkó A, Arrington ME, Swamydas M, Fink D, Das A, Escobedo O, Bonagura V, Szabolcs P, Steinberg HN, Bergerson J, Skoskiewicz A, Makhija M, Davis J, Foruraghi L, Palmer C, Fuleihan RL, Church JA, Bhandoola A, Lionakis MS, Campbell S, Leto TL, Kuhns DB, Holland SM. Hsu AP, et al. Blood. 2019 May 2;133(18):1977-1988. doi: 10.1182/blood-2018-11-886028. Epub 2019 Feb 5. Blood. 2019. PMID: 30723080 Free PMC article. - RCC2 over-expression in tumor cells alters apoptosis and drug sensitivity by regulating Rac1 activation.
Wu N, Ren D, Li S, Ma W, Hu S, Jin Y, Xiao S. Wu N, et al. BMC Cancer. 2018 Jan 10;18(1):67. doi: 10.1186/s12885-017-3908-y. BMC Cancer. 2018. PMID: 29321004 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous